New drug HRS-7535 aims to protect kidneys in diabetes patients
NCT ID NCT06415214
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested HRS-7535, a new drug, in 281 adults with type 2 diabetes and diabetic kidney disease. Participants received either the drug or a placebo for 16 weeks. The main goal was to see if HRS-7535 could reduce protein in the urine, a sign of kidney damage, and help preserve kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-7535
- What this could lead to
- If it works, HRS-7535 could offer a new way to slow kidney damage in people with type 2 diabetes, potentially reducing the need for dialysis or transplant.
- What could go wrong
- This is an early phase 2 trial with only 281 participants, so results may not apply to everyone. The drug may not improve kidney function or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE, TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China